Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma


Dr Jakubowiak discusses interim findings from the ATLAS trial of lenalidomide plus carfilzomib and dexamethasone vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, contextualizes these data within the broader post-transplant landscape, and previews the next steps for this research.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Andrzej Jakubowiak, MD, PhD, a professor of medicine and director of the Myeloma Program at the University of Chicago in Illinois. Dr Jakubowiak joined us to discuss interim findings from the phase 3 ATLAS trial (NCT02659293), which investigated lenalidomide (Revlimid) plus carfilzomib (Kyprolis) and dexamethasone (KRd) vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who had previously received induction therapy and autologous stem cell transplant.

At a median follow-up of 33.8 months, patients who received KRd had a median progression-free survival (PFS) of 59.1 months vs 41.4 months in those who received lenalidomide alone. This translated to a 49% reduction in the risk of progression or death in the KRd arm. Additionally, the ATLAS investigators found a correlation between high minimal residual disease negativity and improved PFS in the KRd arm.

In our exclusive interview, Dr Jakubowiak contextualized the ATLAS findings within the broader post-transplant multiple myeloma treatment landscape, shared pertinent interim data from the trial, and previewed the next steps for this research.


That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Hans C. Lee, MD
Ariel Grajales-Cruz, MD
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Jeffrey Zonder, MD
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Joseph Mikhael, MD, professor, Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute, City of Hope, chief medical officer, International Myeloma Foundation
Ricardo D. Parrondo, MD
Jeffrey Zonder, MD